Immunotherapy Tecentriq Helps Some Advanced-Stage Triple-Neg

I think it's 2 issues;

One is that the Impassion 130 and Impassion 131 came out with different results.

"Approval was based on the progression-free survival (PFS) results of the Phase III IMpassion130 study for people with mTNBC whose tumours express PD-L1 (≥1%). Continued approval for this indication was contingent upon the results of IMpassion131, the postmarketing requirement (PMR). This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population."

Impassion 130 showed benefit, Impassion 131 did not.

THEN, I think Trodelvy also changes things. If there was nothing else on the scene, I wonder if they would have continued to have it as an option. But with Trodelvy being out and showing significant results, the choice most oncologists and pts would make would probably be for Trodelvy....so they would be marketing a drug which few people wanted to use.

Right now in the US, atezolizumab + abraxane are still listed as first line for mTNBC but I think that recommendation might be changing soon? It's still very unclear.

But yes, some people do well on it - it just seems that we are not identifying them. It's probably not PD-L1 that's the relevant marker...

I received Tecentriq in 2019-20. Involved in a clinical trial. Now what happens. Considered NED at this point. I'll have to call study group Monday

Nicole, I don't think they will be prescribing it to new pts but I'm not sure if those responding to it have to go off. Haven't heard details yet.